Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ab Corporate Bond ETF (EYEG)

Ab Corporate Bond ETF (EYEG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family AllianceBernstein
  • Assets Under Management 24,258,500
  • Shares Outstanding, K 700
  • 60-Month Beta N/A
Trade EYEG with:
  • Price/Earnings ttm N/A
  • Annual Dividend & Yield 0.55 (1.57%)
  • Most Recent Dividend 0.157 on 04/01/24
  • Management Fee 0.30%
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.52 +0.39%
on 04/16/24
35.75 -3.06%
on 03/28/24
-0.70 (-1.98%)
since 03/18/24
3-Month
34.52 +0.39%
on 04/16/24
36.02 -3.79%
on 02/01/24
-0.84 (-2.38%)
since 01/18/24

Most Recent Stories

More News
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategy

SALT LAKE CITY, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) is the new name of EyeGate...

KPRX : 0.5100 (+0.75%)
EYEG : 34.65 (-0.20%)
EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and...

EYEG : 34.65 (-0.20%)
EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation

-Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers-

EYEG : 34.65 (-0.20%)
EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update

WALTHAM, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products...

EYEG : 34.65 (-0.20%)
EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

WALTHAM, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for...

EYEG : 34.65 (-0.20%)
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

WALTHAM, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for...

EYEG : 34.65 (-0.20%)
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer

-EyeGate signs non-binding letter of intent to acquire Bayon Therapeutics, a private ophthalmic pharmaceutical company developing a novel, vision restoring small molecule platform-

EYEG : 34.65 (-0.20%)
EyeGate Pharma Announces First Patient Dosed for PP-001 in a Phase 2 Proof-of-Concept Ocular Surface Inflammation Study

- Proof-of-concept study conducted in Austria- -Topline data expected in Q4 2021-

EYEG : 34.65 (-0.20%)
EyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business Update

- PP-001: proof-of-concept study in Austria for dry eye patients expected to initiate in Q3:21; U.S. IND submission planned in Q4:21-

EYEG : 34.65 (-0.20%)
EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors

WALTHAM, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory...

EYEG : 34.65 (-0.20%)

Fund Summary

The AB Corporate Bond ETF seeks to maximize total return through current income and long-term capital appreciation.

See More

Top 10 Holdings

Name % Holdings

See More

Key Turning Points

3rd Resistance Point 34.65
2nd Resistance Point 34.65
1st Resistance Point 34.65
Last Price 34.65
1st Support Level 34.65
2nd Support Level 34.65
3rd Support Level 34.65

See More

52-Week High 36.24
Fibonacci 61.8% 35.58
Fibonacci 50% 35.38
Fibonacci 38.2% 35.18
Last Price 34.65
52-Week Low 34.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar